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In particular, the emergence of multidrug resistant (MDR) 
and extensive drug resistance (XDR) has become a serious problem in 
the treatment of bacterial diseases. Tuberculosis (TB) is a chronic 
infectious disease caused by Mycobacterium of the ‘‘tuberculosis 
complex’’, including primarily M. tuberculosis. Other species M. bovis, M. 
africanum, M. canetti and M. microti can also cause TB, these species do 
not usually infect healthy adults. TB is an airborne communicable 
disease caused by transmission of aerosolized droplets of M. tuberculosis 
(1-5). Mycobacterium belongs to the order actinomycetales, family 
Mycobacteriaceae. Several species, including M. tuberculosis, M. bovis, M. 
africanum, M. microti, M. canetti, M. kansasii, M. avium, and M. leprae, are 
intracellular pathogens of higher vertebrates. The M. tuberculosis 
complex includes three other TB-causing mycobacteria: M. bovis, M. 
africanum and M. microti. The first two only very rarely cause disease in 
immuno competent people. On the other hand although M. microti is not 
usually pathogenic, it is possible that the prevalence of M. microti 
infections has been under estimated. Other Known pathogenic 
mycobacteria include M. leprae, M. avium and M. kansasii (6,7). The last 
two are part of the non tuberculous mycobacterium (NTM) group. The 
NTM cause neither TB nor leprosy, but they do cause pulmonary 
diseases resembling TB. TB requires much longer periods of treatment 
to entirely eliminate mycobacterium from the body (8). Therefore, 
recently attention has focused on the treatment of TB the development 
of new compounds to deal with against MDR and XDR resistant 
mycobacterium species has become one of the most important areas of 
anti-TB research today (9-12). Therefore, recent efforts have been 
directed toward exploring new, potent anti-TB agents with low toxicity 
profiles when compared with anti-TB agents currently in the market 
(13,14). Although, there is an increasing resistance to antimicrobial 
drugs, to overcome the development of drug resistance it is necessary to 
synthesize new antibacterial agents that possessing different chemical 
properties as well as less toxic effect from those of used commonly. 
 
2. Tuberculosis an Overview 
Tuberculosis (TB) is one of the oldest and most pervasive, 
respiratory transmitted diseases in history. According World Health 
Organization (15) report, TB has spread to every corner of the globe. As 
much as one-third of the world's population is currently infected, more 
than any other infectious disease (16). It was estimated that nearly 1 
billion more people will be infected with TB in the next 20 years (17). 
The occurrence of TB is linked to dense population, poor sanitation and 
poor nutrition (18). Direct Observed Treatment, short-course (DOTS) 
strategy, constitutes the cornerstone of the current protocol for control 
of TB. However, the three key drugs, isoniazide, pyrazinamide and 
rifampicin, used in the regimen are potentially hepatotoxic and may lead 
to drug associated hepatitis. Despite the undoubted success of DOTS 
strategy, the emergence of MDR resistant strains, recurrently isolated 
from patient's sputum, darken the future (19). The increase in TB 
incidence during recent years is largely due to the prevalence of TB is 
synergy with Human Immunodeficiency Virus (HIV) epidemic, which 
augments the risk of developing the disease 100-fold and also the 
emergence of MDR-TB strains. In addition to this, the increase in M. 
tuberculosis strains resistant to front line antiTB drugs such as rifampin 
and INH has further complicated the problem, which clearly indicates 
the need for more effective drugs for the efficient management of TB 
(20-22). 
2.1 Need of new Antitubercular Drugs:  
A new TB treatment should offer following three 
improvements over the existing regimens: shorten the total duration of 
treatment and/or significantly reduce the number of doses, improve the 
treatment of MDR-TB and XDR-TB, provide a more effective treatment 
of latent TB infection (23,24). In order to analyse useful to group drug 
candidates currently in two main categories: 1) Novel chemical entities 
and 2) Compounds originating from existing families of drugs, where 
innovative chemistry is used to optimise the compounds. Drug 
resistance (MDR and XDR) by M. tuberculosis is an important obstacle 
for the treatment and control of TB. The MDR-TB refers to simultaneous 
resistance to at least two or more of the five first-line anti-TB drugs 
(isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin) 
(25). Treatment for MDR-TB is long lasting, less effective, costly, and 
poorly tolerated (26-29). The XDR-TB by definition is resistance to at 
least isoniazid and rifampicin in addition to any quinolone and at least 
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one injectable second-line agent (capreomycin, amikacin, kanamycin). 
The principles of treatment for MDR-TB and XDR-TB are the same. The 
main difference is that XDR-TB is associated with a much higher 
mortality rate than MDR-TB, because of reduced number of effective 
treatment options (30-32). Hence there is an urgent need for novel 
drugs that are active against M. tuberculosis in order to shorten the 
duration of TB therapy. 
2.2 Current chemotherapy of Tuberculosis 
Current chemotherapy of TB are mainly depends on first-line 
anti-TB drugs, which include streptomycin, isoniazid, rifampicin, 
ethambutol and pyrazinamide, they more effective and less toxic as 
compare to second-line anti-TB drugs. Second line anti-TB drugs are 5 
or 6 classeses of drugs. Second-line drug may be less effective than the 
first-line drugs or it may have toxic side-effects or. These comprise of 
different classes namely, aminoglycosides (amikacin, kanamycin), 
polypeptides (capreomycin, viomycin), fluoroquinolones (ciprofloxacin, 
moxifloxacin, etc), thioamides: (ethionamides, prothioamide), 
cycloserine and p-aminosalicylic acid (1,33). 
2.2 Toxic Effects of Currenly Used Antitubercular Agents:  
The currently available key medications (first line) used in 
the regimen are show serious side effects like severe damage to the 
eighth cranial nerve, inducing irreversible impairment of auditory 
function, hypersensitivity reactions (streptomycin), potentially 
hepatotoxic and may lead to drug associated hepatitis (isoniazide, 
pyrazinamide and rifampicin (rifampicin, rifabutin, rifapentine) and 
thrombocytopenic purpura (rifampicin) (34-37). Second line anti-tb 
drugs are more toxic than first line drugs, amikacin and kanamycin 
causes kidney damage as well as hearing loss, viomycin and 
capreomycin causes nephrotoxicity and eighth cranial nerve toxicity. 
Fluoroquinolones (ciprofloxacin, moxifloxacin, ofloxacin (levofloxacin, 
the chiral form of ofloxacin is more effective), gatifloxacin, trovafloxacin, 
enofloxacin and sparfloxacin etc). Fluoroquinolones are increasingly 
contraindicated for patients due to growing prevalence of antibiotic 
resistance. Ethionamid and prothionamide (structural analogues of 
isoniazid) causes adverse effects are g.i.t. disorders (anorexia, salivation, 
nausea, abdominal pain, and diarrhea), mental disturbances 
(depression, anxiety, psychosis, dizziness, drowsiness, and headache) 
and hypersensitivity (38-40). Cycloserine causes side effects of this drug 
are mainly CNS manifestations such as headache, irritability, depression, 
convulsions. Para amino salicyclic acid causes g.i.t. problems including 
anorexia, nausea, epigastric pain, abdominal distress, diarrhea, ulcers 
and hypersensitivity (41,42).   
 
3. Compounds Originating From Existing Drug Pyrazinmide 
The five first-line drugs for treatment are highly effective and 
the rate of severe adverse reactions is low and six classes of second line 
drugs, it may be less effective than the first-line drugs or it may have 
more toxic side-effects (43-49). However, unpleasant side effects, 
relatively long duration of treatment and non-compliance to treatment 
regimen are drawbacks. Such non-adherence with the course of 
treatment leads to treatment failure and the development of drug 
resistance. The second line drugs used for MDR-TB are more expensive, 
less effective and more toxic than the five drug standard regimen. The 
goal now is to develop bactericidal drugs in a cost-effective manner, 
which efficaciously treats infectious MDR/XDR strains of M. tuberculosis 
and latent infections with shortened treatment periods as well as 
reduced frequency of dosage. Some of recently discovered first line drug 
analogues as anti-Tb agents are discussed below (50-52). 
3.1 Pyrazinamide (Aldinamide):  
Pyrazinamide (1) is the synthetic pyrazine analog of 
nicotinamide. Pyrazinamide exhibits bactericidal activity in vitro only at 
a slightly acidic pH. Activity at acid pH is ideal, since M. tuberculosis 
resides in an acidic phagosome within the macrophage. Tubercle bacilli 
within monocytes in vitro are inhibited or killed by the drug at a 
concentration of 12.5µg/ml. Resistance develops rapidly if PZA is used 
alone. The target of pyrazinamide appears to be the mycobacterial fatty 
acid synthase I gene involved in mycolic acid biosynthesis (53-57).  
Pyrazine analog of nicotinamide and mechanism suspected to 
be similar to isoniazid based mostly on structural similarity, not direct 
evidence. It also has to be metabolically activated. PZA-resistant strains 
of M. tuberculosis have a mutation in the hydrolase gene. Pyrazinamide 
(I) is indicated for the initial treatment of active tuberculosis in adults 
and children when combined with other anti-TB agents. PZA is an 
important sterilising tuberculosis drug that helps to shorten the 
duration of current chemotherapy regimens for tuberculosis. It is 
unique among antituberculosis drugs in having no genomic site of action 
and having greater bactericidal activity as bacillary metabolism slows 
down; it is remarkably effective in human disease. PZA is an important 
component in the intensive phase of short-course treatment of TB owing 
to its sterilising activity, ability to work acidic environments (in 
macrophages), and excellent synergy with RIF (58,59). Pyrazinamide 
appears to kill at least 95% of the semi-dormant bacterial population 
persisting in a low-pH environment since its activity is present only in 
the acidic environment found in active inflammation (60). The 
development of a new drug with a similar mode of activity might be very 
fruitful, especially if there were no need for an acid environment (61). 
Objectives for Understanding TB drug development are: (i) to shorten 
the total duration of effective treatment and/or significantly reduce the 
total number of doses needed to be taken under directly observed 
treatment, short-course (DOTS) supervision, (ii) to improve the 
treatment of MDR-TB, which cannot be treated with INH and RMP, and 
(iii) to provide a more effective treatment of latent TB infection (LTBI). 
Genomics, the systematic identification of all of the genes in a cell 
through deoxyribonucleic acid (DNA) sequencing and bioinformatic 
analysis, also offers great potential in terms of drug target discovery and 
development of new antibacterial agents, and the recently sequenced 
genome of M. tuberculosis should provide a number of new targets for 
novel drugs. 
Pyrazinamide is well absorbed from the gastrointestinal tract 
and widely distributed throughout the body. The drug is excreted 
primarily by renal glomerular filtration. Pyrazinamide is distributed 
widely-including to the CNS, lungs, and liver after oral administration. 
Penetration of the drug into the CSF is excellent. Pyrazinamide is 
hydrolyzed to pyrazinoic acid and subsequently hydroxylated to 5-
hydroxypyrazinoic acid, the major excretory product. Pyrazinamide has 
become an important component of short-term (6-month) multiple-
drug therapy of tuberculosis.  
3.2 Untoward Effects:  
Injury to the liver is the most serious side effect of 
pyrazinamide such as hepatic disease, jaundice, hepatic necrosis. 
Elevations of plasma alanine and aspartate aminotransferases are the 
earliest abnormalities produced by the drug. The drug inhibits excretion 
of urate, resulting in hyperuricemia in nearly all patients; acute episodes 
of gout have occurred. Other untoward effects that have been observed 
with pyrazinamide are arthralgias, anorexia, nausea and vomiting, 
dysuria, malaise, and fever. While some international organizations 
recommend the use of pyrazinamide in pregnancy, this is not the case in 
the United States because of inadequate data on teratogenicity (62-67). 
3.3 Modifications of PZA structure:  
The PZA and pyrazinoic acid (POA) as potential analeptic 
drugs and intermediate compounds on the pathway of aminopyrazine 
synthesis (68), but the anti-TB activity of PZA was reported later, in 
1952. The use of nicotinamide-related compounds for the therapy of TB 
followed the unexpected observation that nicotinamide was effective for 
the treatment of murine TB. The initial information that nicotinamide 
possessed modest anti-TB activity stimulated the evaluation of other 
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derivatives. This observation led to the subsequent discovery of not only 
PZA but also INH (69) and ethionamide. Of many nicotinamide 
analogues that were subsequently evaluated for anti-TB activity, only 
PZA was active in vivo (70-72). In the same year (73) the synthesis of 49 
PZA derivatives and 14 related compounds was reported, and their anti-
TB activities in the in vivo murine system were briefly referred to, but no 
information on their in vitro anti-TB activities was provided. It was soon 
shown that an enzyme called nicotinamidase inside the mycobacterium 
hydrolyzed nicotinamide and pyrazinamide to the corresponding 
carboxylic acids, and these carboxylic acids were the actual active 
compounds (74). However, nicotinic and pyrazinoic acids did not 
demonstrate activity due to their poor penetration into mycobacterial 
cells. PZA is still unusual because of its narrow spectrum of activity. 
Several aminomethylene analogues/prodrugs of PZA were prepared and 
evaluated including morphazinamide (2), which is a morpholine 
derivative, Mannich base of PZA (75); the lack of any demonstrable 
improvement over PZA in vivo led to its abandonment. Surprisingly, it 
was found that amides of 5-substituted pyrazinoic acid displayed good 
activity against M. avium, PZA-resistant M. tuberculosis, and 
phagocytized M. tuberculosis, and these compounds also showed activity 
over a broad range of pH values (76). M. avium became a serious cause 
of disseminated infection among patients with AIDS. Novel 
aminomethylene analogues of PZA (3) were tested (77). The activity of 
N-(pyrrolidin-1-ylmethyl)pyrazine-2- carboxamide was higher than that 
of PZA when administered with rifalazil or RIF in a mouse model of 
infection. The activity of these analogues against PZA-resistant strains 
suggests that development of the second generation PZA analogues may 
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Fig. 1: Structures of Pyridazine and aminomethylene analogues of 
Pyridazine 
PZA exhibits remarkably stringent structure-activity 
relationships (SAR) demonstrating an absolute requirement for the 
pyrazine nucleus and the carboxamide moiety in position 2 for the 
activity. The modifications of the pyrazine ring with pyridazine and/or 
pyrimidine were not successful (78). It can be concluded that any 
isosteric replacement of carbon by nitrogen or shift of nitrogen to 
another position results in the loss of antimycobacterial activity. Also 
ortho-condensation of the aromatic/heteroaromatic ring with pyrazine 
nucleus did not lead to active compounds. Similarly, the substitution of 
the carboxamide group in thioamide, N-methyl, N-acetyl, hydrazide 
(analogy with INH), nitrile, tetrazole and free carboxylic acid provided 
compounds that were completely inactive in vivo (73). One of the 
effective methods that can lead to new drug discovery is the bioisosteric 
replacement of a functional group. Numerous functional groups have 
been reported as bioisosteric replacements for the carboxylic acid 
functionality (79). The prodrug approach in series of PZA derivatives is 
already very hopeful. Substituted pyrazinecarboxylic acid esters have 
been previously reported to have in vitro activity against M. avium and 
M. kansasii as well as M. tuberculosis. Modification of both the pyrazine 
nucleus and the ester functionality was successful in expanding the anti-
TB activity associated with PZA to include M. avium and M. kansasii, 
organisms usually not susceptible to pyrazinamide. In an attempt to 
understand the relationship between the activities of the esters and the 
needed biostability, quantitative structure-activity relationships (QSAR) 
were found (80). While POA cannot pass through mycobacterial cell 
walls due to its low lipophilicity, the esterification of POA is a suitable 
approach to increase the likelihood of its penetration into the resistant 
mycobacteria (81,82). Thus series of POA esters were prepared and 
evaluated. PZA-resistant isolates became susceptible in vitro to 
pyrazinoic acid, and n-propyl pyrazinoate was the most promising 
candidate (4). Esters of POA appeared to circumvent the requirement 
for activation by mycobacterial amidase. The MICs of n-propyl 
pyrazinoate for M. tuberculosis isolates were lower than those of 
pyrazinoic acid. This may lead to a candidate compound with enhanced 
activity against both PZA-susceptible and PZA-resistant M. tuberculosis 
isolates suitable for clinical development (82,83). However, efficacy 
studies in mice failed to show any anti-TB activity likely due to poor 
stability of the esters in plasma. Another series of more lipophilic ester 
prodrugs (i.e. tetradecyl ester) were found to be active in concentrations 
10-fold lower than those needed for PZA to kill sensitive M. tuberculosis 
and also have suitable stability in the presence of plasma (84). These 
relationships are consistent with the observation that tert-butyl 5-
chloropyrazine-2-carboxylate and 2-methyldecyl 5-chloropyrazine-2-
carboxylate are 100-fold more active than PZA against M. tuberculosis 
and exhibit serum stability 900-1000 times greater than the lead 
compounds in the series. Some 5-hydroxypyrazine-2-carboxylic acid 
derivatives (5) are up to 1000-fold more active against M. tuberculosis 
and other Mycobacterium strains than existing antituberculous agents 
(85); synthesis of compounds 5 is important, because it is a building 
block for the synthesis of new anti-TB agents. 5-Hydroxypyrazine-2-
carboxylic acid can be produced microbiologically by whole-cell 
biotransformation of 2-cyanopyrazine (86). Various substituted 
analogues of PZA with bioisosteric replacements of the carboxylic acid 
functionality were prepared. Thus 5-aroylpyrazine-2-carboxylic acid 6, 
(87) and arylsulfanyl pyrazinecarboxylic acid (7), (88) derivatives were 






















Fig. 2 Structures of pyrazine-2-carboxylic acid derivatives. 
 In order to find more active PZA derivatives, various PZA 
analogues were synthesized and assayed against M. tuberculosis (89). In 
these experiments, four compounds showed high levels of anti-TB 
activities, not only bacteriostatic but also bactericidal, against M. 
tuberculosis as well as M. avium complex (MAC). These compounds, 
namely, pyrazinoic acid pivaloyloxymethyl ester, pyrazinoic acid n-octyl 
ester, pyrazinethiocarboxamide and N-
hydroxymethylpyrazinethiocarboxamide, may warrant further 
examinations. 5-Chloropyrazine-2-carboxamide (8) showed excellent in 
vitro activity against PZA-resistant strains of M. tuberculosis (90). 
Therefore FAS I and/or FAS II were proposed as a target of this 
compound, i.e. this compound possesses a different mechanism of action 
(91). Due to this fact 3-chloropyrazine-2,5-dicarbonitrile (9), and 6-
chloro-5-cyanopyrazine-2-carboxamide (10), (92,93) and their 
derivatives were synthesized, and their noteworthy anti-TB activities 
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Fig. 3 Structures of chloropyrazine derivatives. 
3.4 Anti-Mycobacterium tuberculosis bioassays 
 Several in vitro bioassays have been developed to evaluate 
antitubercular activity of chemical compounds. In most of these 
methods, Mycobacterium is cultured in various types of broth- and agar-
based media. But, the main problems are long growth time (several 
weeks) and its pathogenicity, hence containment facilities are required. 
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The common conditions for the anti-TB susceptibility evaluation are 
influenced by acid-base properties of medium (94). For nearly two 
decades the radiometric BACTEC 460 TB System provided the most 
rapid method for antimicrobial susceptibility testing (95). 
3.5 In vitro bioassays 
The primary screening was conducted at 6.25µg/mL against 
M. tuberculosis H37Rv (ATCC 27294) in BACTEC 12B medium using the 
Microplate Alamar Blue Assay (MABA). In general, compounds effecting 
>90% inhibition in the primary screening (MIC <6.25µg/mL) were 
further evaluated. The initial screening was conducted against M. 
tuberculosis H37Rv (ATCC 27294) in BACTEC 12B medium using the 
MABA (96). The following was synthesized in preference: (i) compounds 
with lipophilic and/or electron-withdrawing substituents on the 
benzene moiety (R3), (ii) compounds with hydrophilic and/or electron-
donating groups on the benzene part of the molecule (R3), and finally 
(iii) compounds with a lipophilic alkyl chain (R2), i.e. tert-butyl (-
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Fig. 4 Structure of substituted N-phenylpyrazine-2-carboxamides (11) 
and substituted N-(thiazol-2-yl)pyrazine-2-carboxamides (12). 
 
4. Discussions  
In the recent past, drug discovery efforts shifted towards the 
drug design based on docking studies. These docking computational 
techniques allow investigating the possible binding modes of a substrate 
to a given receptor, enzyme or another binding site and consequently 
determining and identifying the precise or different mechanism of 
action of both PZA and its derivatives, e.g. 5-chloropyrazine-2-
carboxamide (8) and similar compounds. Therefore the priority is to 
isolate the enzymes (from M. tuberculosis and subsequently from cells of 
other Mycobacterial strains) responsible for metabolization/activation 
of PZA and other enzymes that can be influenced by POA generation, e.g. 
FAS I, FAS II, etc. After isolation and determination of 3D structure by X-
Ray structural analysis, it will be needed to crystallize enzymes with 
PZA and other PZA derivatives, determine 3D structures of these 
complexes and develop 3D-pharmacophore for systematic virtual 
screening based on this process. Then it will be possible to evaluate all 
PZA-like derivatives based on their virtual binding simulation and to 
carry out their evaluation using a large set of distance-based topological 
indices. In addition, various molecular descriptors can be used. As most 
pyrazine derivatives seem to be prodrugs and their activity is strongly 
dependent on the rate of hydrolysis to POA, further in vitro experiments 
with isolated enzymes should be focused on determination of the 
hydrolysis rate. Also compounds of interest will be subject to in vivo 
studies for determination of their efficacy against murine M. tuberculosis 
(98-100). PZA is a cornerstone drug of current TB therapy and emerged 
as an important building block for regimens with promise to shorten TB 
treatment. PZA is a prodrug which must be activated by the M. 
tuberculosis enzyme pyrazinamidase within the bacterium in order to 
exert its anti-TB activity. The project was focused on discovery of PZA 
analogues with PZA-like efficiency characteristics along with improved 
potency and increased safety. The main task was search for new anti-TB 
pyrazines-structure analogues of PZA (101-103). Biological evaluation 
comprised of anti-TB activity screening as the main task. The 
compounds relieved into level 2 testing underwent MIC and CC50 
determination followed by Selectivity Index calculation (SI, ratio of 
measured CC50 to MIC). To be relieved to level 3 (in vivo screening) the 
compound had to exhibit SI>10. The in vivo screening of compound 1 
was not finished yet. The results of this project could be a very good 
starting point for the advanced drug design and development of new 
anti-TB agents based on pyrazine. In view of the persistent drug-
resistant TB problem of currently used anti-TB drugs, it is important 
that new anti-TB molecules or drugs should address different targets, as 
those of currently used drugs including the shortening of TB therapy. 
The unique structure of the mycobacterial cell wall makes it a useful 
target for drug development (104,105). The identification of novel 
target sites will also be needed to circumvent the problems associated 
with the increasing occurrence of MDR and XDR strains (106-108). 
Many unique metabolic processes occur during the biosynthesis of 
mycobacterial cell wall components. For example, one of these attractive 
targets for the rational design of new antitubercular agents are the 
mycolic acids, the major components of the cell wall of M. tuberculosis 
(109-112). From the chemotherapeutic point of view, there are two 
sources of new chemical entities. The first is the extraordinary diversity 
provided by new molecules. The second results from the design of new 
or the modernization of synthetic transformations. 
 
5. Conclusion 
 Tuberculosis remains a leading infectious killer worldwide. 
Development of new anti-TB drugs is the need to control TB. In the last 
fourty years no new compound has been brought to the market for the 
treatment of TB. However, in recent years there is an enhanced activity 
in the research and development of new drugs for TB. Some compounds 
are presently in clinical development, while others are being 
investigated pre-clinically in an attempt to explore new molecules for 
the target based treatment of TB. Simultaneously some new targets are 
being identified and validated for their practical usefulness. This is 
mainly due to the lack of new drugs, particularly effective against the 
MDR and XDR strains, and patients co-infected with HIV/AIDS. 
Therefore, there is an urgent need of new anti-TB drugs with lesser side-
effects, improved pharmacokinetics and effective against MDR and XDR 
bacterial strains with reduce the overall duration of treatment. 
Precisely, it is imperative to develop smart new drugs that inhibit novel 
targets that are structurally and functionally different from those 
currently known.  Medicinal chemists will be interested to working on 
new compounds. In view of above facts, various new drugs will be 
synthesized in the future for development of new effective molecule. 
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